# TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer

> **NCT07271992** · PHASE2 · NOT_YET_RECRUITING · sponsor: **First Hospital of China Medical University** · enrollment: 30 (estimated)

## Conditions studied

- TNBC, Triple Negative Breast Cancer

## Interventions

- **DRUG:** SG+I

## Key facts

- **NCT ID:** NCT07271992
- **Lead sponsor:** First Hospital of China Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2030-12-14
- **Final completion:** 2031-12-14
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07271992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07271992, "TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07271992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*